Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Research & Development (2018 - 2025)

Historic Research & Development for Sunshine Biopharma (SBFM) over the last 12 years, with Q3 2025 value amounting to $119298.0.

  • Sunshine Biopharma's Research & Development fell 559.03% to $119298.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $680079.0, marking a year-over-year decrease of 5752.05%. This contributed to the annual value of $933902.0 for FY2024, which is 4967.74% down from last year.
  • Sunshine Biopharma's Research & Development amounted to $119298.0 in Q3 2025, which was down 559.03% from $196232.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Research & Development registered a high of $816328.0 during Q4 2023, and its lowest value of $41763.0 during Q4 2022.
  • In the last 5 years, Sunshine Biopharma's Research & Development had a median value of $215277.0 in 2025 and averaged $252874.0.
  • Per our database at Business Quant, Sunshine Biopharma's Research & Development soared by 517766.2% in 2021 and then plummeted by 8171.42% in 2024.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Research & Development stood at $91198.0 in 2021, then plummeted by 54.21% to $41763.0 in 2022, then surged by 1854.67% to $816328.0 in 2023, then tumbled by 81.71% to $149272.0 in 2024, then fell by 20.08% to $119298.0 in 2025.
  • Its last three reported values are $119298.0 in Q3 2025, $196232.0 for Q2 2025, and $215277.0 during Q1 2025.